Tag #Dermatomyositis

What is the significance of the successful CAR-T therapy treatment for anti-MD5 dermatomyositis at Hospital Universitario La Paz?

The Hospital Universitario La Paz in Madrid successfully treated a child with anti-MD5 dermatomyositis, a rare autoimmune disease with a 30-66% mortality rate, using CAR-T cell therapy—a world first. The therapy, ARI-0001, redirected the patient's immune system, eliminating the need for over 10 immunosuppressant treatments and resulting in remission after one year. This is a significant breakthrough given the disease's high mortality and lack of specific treatments.